JP2000509394A5 - - Google Patents

Download PDF

Info

Publication number
JP2000509394A5
JP2000509394A5 JP1997539221A JP53922197A JP2000509394A5 JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5 JP 1997539221 A JP1997539221 A JP 1997539221A JP 53922197 A JP53922197 A JP 53922197A JP 2000509394 A5 JP2000509394 A5 JP 2000509394A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997539221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000509394A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/007335 external-priority patent/WO1997040854A2/en
Publication of JP2000509394A publication Critical patent/JP2000509394A/ja
Publication of JP2000509394A5 publication Critical patent/JP2000509394A5/ja
Ceased legal-status Critical Current

Links

JP9539221A 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体 Ceased JP2000509394A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1634796P 1996-05-01 1996-05-01
US2860996P 1996-10-23 1996-10-23
US60/016,347 1996-10-23
US60/028,609 1996-10-23
PCT/US1997/007335 WO1997040854A2 (en) 1996-05-01 1997-04-30 Polypeptide conjugates for transporting substances across cell membranes

Publications (2)

Publication Number Publication Date
JP2000509394A JP2000509394A (ja) 2000-07-25
JP2000509394A5 true JP2000509394A5 (OSRAM) 2004-12-09

Family

ID=26688485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9539221A Ceased JP2000509394A (ja) 1996-05-01 1997-04-30 細胞膜を横切って物質を輸送するためのポリペプチド結合体

Country Status (5)

Country Link
EP (1) EP0966303A2 (OSRAM)
JP (1) JP2000509394A (OSRAM)
AU (1) AU729643B2 (OSRAM)
CA (1) CA2252706A1 (OSRAM)
WO (1) WO1997040854A2 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291617T1 (de) * 1997-01-24 2005-04-15 Avi Biopharm Inc Verfahren und konjugat zur behandlung von helicobacter pylori-infektionen
US6455495B1 (en) * 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
WO1998052614A2 (en) 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US20020064520A1 (en) * 1999-08-19 2002-05-30 Yanina Rozenberg Targeted artificial gene delivery
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2002004479A1 (en) 2000-07-06 2002-01-17 Avi Biopharma, Inc. TRANSFORMING GROWTH FACTOR BETA (TGF-β) BLOCKING AGENT-TREATED STEM CELL COMPOSITION AND METHOD
ES2617692T3 (es) 2000-07-21 2017-06-19 Revance Therapeutics, Inc. Sistemas de transporte de agentes biológicos de múltiples componentes
JP2004523480A (ja) * 2000-08-22 2004-08-05 ニュー リバー ファーマシューティカルズ, インコーポレイテッド 活性作用物質送達系ならびに活性作用物質の保護および投与方法
JP2006516948A (ja) * 2000-11-14 2006-07-13 ニュー リバー ファーマシューティカルズ インコーポレイテッド 硫酸アバカビルを含有する新規な薬剤化合物および同化合物の製造ならびに使用方法
AU2003217676B2 (en) * 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
WO2005072527A2 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
MXPA06009897A (es) 2004-03-03 2008-02-07 Revance Therapeutics Inc Composiciones y metodos para el diagnostico topico y el transporte terapeutico.
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005327188C9 (en) 2004-07-02 2011-09-22 Avi Biopharma, Inc. Antisense antibacterial method and compound
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
PL2360258T3 (pl) 2005-02-18 2015-03-31 Angiochem Inc Polipeptydy aprotyniny do transportowania związków przez barierę krew-mózg
MX2007010673A (es) 2005-03-03 2008-04-07 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
EP1856139B1 (en) 2005-03-03 2011-04-27 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of an oligopeptide
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009117553A2 (en) 2008-03-20 2009-09-24 University Of Florida Research Foundation, Inc. Enhancing vessel lesion homing and repair potential of stem cells
EP2143726A1 (en) * 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8592386B2 (en) * 2008-12-17 2013-11-26 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
EP2437772B1 (en) 2009-06-05 2017-12-06 13Therapeutics, Inc. Immunoregulatory peptides and methods of use
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
US8580748B2 (en) 2011-04-06 2013-11-12 13Therapeutics, Inc. Peptides for the treatment of hearing
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
US9278987B2 (en) 2011-11-18 2016-03-08 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
EA031110B1 (ru) 2012-03-20 2018-11-30 Сарепта Терапьютикс, Инк. Конъюгаты бороновых кислот олигонуклеотидных аналогов
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
WO2017062699A1 (en) * 2015-10-07 2017-04-13 Cormedix Inc. Skin-penetrating formulation of taurolidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates
EP0932399B1 (en) * 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs

Similar Documents

Publication Publication Date Title
JP2000502280A5 (OSRAM)
JP2000501599A5 (OSRAM)
JP2000501018A5 (OSRAM)
JP2000500076A5 (OSRAM)
JP2001501490A5 (OSRAM)
JP2001500986A5 (OSRAM)
JP2000501324A5 (OSRAM)
JP2000515705A5 (OSRAM)
JP2000500055A5 (OSRAM)
JP2000500026A5 (OSRAM)
JP2001500878A5 (OSRAM)
JP2000501338A5 (OSRAM)
JP2000501825A5 (OSRAM)
JP2000500874A5 (OSRAM)
JP2000509394A5 (OSRAM)
JP2000502425A5 (OSRAM)
JP2000517213A5 (OSRAM)
JP2000501774A5 (OSRAM)
JP2000500912A5 (OSRAM)
JP2000501876A5 (OSRAM)
JP2001503025A5 (OSRAM)
JP2000501744A5 (OSRAM)
JP2000501229A5 (OSRAM)
JP2000500857A5 (OSRAM)
JP2000502316A5 (OSRAM)